Clearside Biomedical
CLSD
CLSD was delisted on the 28th of November, 2025.
48 hedge funds and large institutions have $12.8M invested in Clearside Biomedical in 2024 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 9 increasing their positions, 13 reducing their positions, and 9 closing their positions.
203% more call options, than puts
Call options by funds: $194K | Put options by funds: $64K
11% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 9
2% more funds holding
Funds holding: 47 → 48 (+1)
0.33% less ownership
Funds ownership: 1.23% → 0.9% (-0.33%)
29% less capital invested
Capital invested by funds: $17.9M → $12.8M (-$5.15M)
31% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
First Manhattan
New York
|
+$559K |
| 2 |
GGH
GCM Grosvenor Holdings
Chicago,
Illinois
|
+$226K |
| 3 |
Renaissance Technologies
New York
|
+$185K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$142K |
| 5 |
PNC Financial Services Group
Pittsburgh,
Pennsylvania
|
+$116K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RA
Rosalind Advisors
Toronto,
Ontario, Canada
|
-$2.81M |
| 2 |
AC
Armistice Capital
New York
|
-$2.78M |
| 3 |
CG
Carmignac Gestion
Paris,
France
|
-$227K |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$80.8K |
| 5 |
BCV
Banque Cantonale Vaudoise
Lausanne,
Switzerland
|
-$52K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
51
Marshall Wace
London,
United Kingdom
| – | -$80.8K | -4,141 | Closed |
|
|
BCV
52
Banque Cantonale Vaudoise
Lausanne,
Switzerland
| – | -$52K | -2,667 | Closed |
|
53
Jane Street
New York
| – | -$37.3K | -1,913 | Closed |
|
|
CRC
54
Curi RMB Capital
Chicago,
Illinois
| – | -$32.5K | -1,667 | Closed |
|
|
TSS
55
Two Sigma Securities
New York
| – | -$24.4K | -1,253 | Closed |
|
56
RhumbLine Advisers
Boston,
Massachusetts
| – | -$1.42K | -73 | Closed |
|
57
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$1K | -38 | Closed |
|
58
Wells Fargo
San Francisco,
California
| – | -$65 | -3 | Closed |
|
59
Qube Research & Technologies (QRT)
London,
United Kingdom
| – | -$5 | – | – |
|
CLSD Hedge Fund Activity: Q3 2024 in Review
48 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Clearside Biomedical (CLSD) for Q3 2024, worth a combined $12.8M — down 29% from $17.9M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new CLSD positions and 9 closed out — a net gain of 1 holder — while 9 added to existing stakes and 13 trimmed.
The largest buyer was First Manhattan, adding an estimated $559K. The largest seller was Rosalind Advisors, cutting an estimated $2.81M.
- 48 institutional investors held Clearside Biomedical (CLSD) as of Q3 2024, up from 47 in Q2 2024.
- Funds reported $12.8M of Clearside Biomedical stock for Q3 2024, down 29% quarter-over-quarter.
- 10 funds opened new Clearside Biomedical positions in Q3 2024 and 9 closed out, a net change of +1 holder.
- The largest Clearside Biomedical buyer in Q3 2024 was First Manhattan, an estimated $559K added.
- The largest Clearside Biomedical seller in Q3 2024 was Rosalind Advisors, an estimated $2.81M sold.
Based on aggregated 13F filings for Q3 2024.